Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $48
Barclays has reiterated its Buy rating on Collegium Pharmaceutical (COLL.US) but has reduced its price target for the company's stock to $48. This indicates a continued positive outlook on the stock's performance, albeit with a slightly adjusted valuation expectation.
Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock
Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts for advisory clients who retain the rights to dividends and sale proceeds. This disclosure was made via a SCHEDULE 13G filing with the SEC.
COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56
Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) program with Jefferies LLC, as part of a larger $150 million share repurchase authorization. The company believes its current valuation does not fully reflect its strong financial position, growing ADHD portfolio, and future prospects, making the share repurchase a compelling opportunity to create long-term shareholder value. The ASR is expected to be completed by the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com
Collegium Pharmaceutical announced an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. This is part of a larger $150 million share repurchase program authorized by the company's Board of Directors in July 2025, leaving $100 million remaining after this transaction. The final number of shares will be based on volume-weighted average prices and is expected to settle no later than the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock
Collegium Pharmaceutical announced an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. This action is part of a larger $150 million share repurchase program authorized in July 2025, leaving $100 million remaining after this transaction. The company will initially receive 1,556,420 shares, with the final number determined by volume-weighted average prices during the ASR term, and attributes this move to its strong financial position and robust cash generation.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) program with Jefferies LLC, part of a larger $150 million authorization. The company believes its current valuation undervalues its business strength and future prospects, especially given its growing ADHD portfolio and robust cash generation. This move is intended to create long-term shareholder value and is expected to be completed by the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com
Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock, part of a larger $150 million share repurchase program. The company will receive an initial delivery of 1,556,420 shares, representing about 80% of the total expected repurchase, with the final settlement anticipated by the fourth quarter of 2026. This move highlights Collegium's strong financial position and disciplined capital allocation strategy.
Collegium Pharmaceutical Launches $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. has initiated a $50 million accelerated share repurchase program with Jefferies LLC, utilizing part of its $150 million authorization. This move aims to return cash to shareholders while the company continues to invest in its drug portfolio and reduce debt. The company believes its current valuation does not fully reflect the growth potential of its ADHD portfolio or the durability of its pain business.
Collegium gains on accelerated share buybacks (COLL:NASDAQ)
Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by Collegium.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of its larger $150 million share repurchase program authorized in July 2025. This move reflects the company's strong financial position and confidence in its ADHD portfolio, aiming to enhance long-term shareholder value. The ASR is expected to be completed by the fourth quarter of 2026, with 1,556,420 shares initially delivered based on the closing stock price on August 12, 2026.
Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program
Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price (VWAP) during the ASR term, expected to settle by Q4 2026. The company had approximately 32.5 million shares outstanding as of June 30, 2026.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its current valuation does not fully reflect its strong financial position, rapidly growing ADHD portfolio, and robust cash generation, making the share repurchase a compelling opportunity to create long-term shareholder value.
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. Analysts focused on generic pricing stabilization, Azstarys' demand drivers, dual ADHD product promotion, and future capital deployment for CNS and rare disease assets.
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Collegium Pharmaceutical (COLL) missed Q2 CY2026 revenue expectations but beat non-GAAP profit estimates, with sales increasing 6.3% year-on-year. The company's revenue guidance for the full year was lifted, primarily due to strong performance in its ADHD business, particularly Jornay PM and the integration of Azstarys. However, the pain management segment, especially the NUCYNTA franchise, faced headwinds from pricing pressure, which is expected to continue to impact overall performance despite stabilization.
Collegium Pharmaceutical, Inc. $COLL Shares Acquired by Sei Investments Co.
Sei Investments Co. significantly increased its stake in Collegium Pharmaceutical, Inc. ($COLL) by 191.6% in the first quarter, acquiring 85,830 additional shares, bringing its total holding to 130,620 shares valued at approximately $4.32 million. Other institutional investors also adjusted their positions, with Jennison Associates LLC initiating a new position. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $57.50, following recent earnings that surpassed estimates.
Collegium Pharmaceutical, Inc. Revenue Breakdown – NASDAQ:COLL
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) generated $780.57 million USD in revenue last year, primarily from its Pharmaceutical segment. This marks an increase from the previous year's $631.45 million USD, with the United States being the sole contributor to this revenue. The financial data highlights the company's strong performance in its core pharmaceutical business within the US market.
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze
Collegium Pharmaceutical (COLL) experienced a 1.2% stock increase after Q2 earnings, despite swinging from a profit to a net loss of US$15.1 million. While revenue grew to US$199.9 million, driven by its ADHD portfolio, the company faced a significant margin squeeze due to acquisition costs and authorized generics in pain treatments. This situation raises concerns about the long-term earnings path, despite the company's efforts to diversify beyond its pain-focused origins.
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze
Collegium Pharmaceutical (COLL) saw its stock inch up 1.2% despite swinging from a Q1 profit to a Q2 loss, primarily due to a deepening margin squeeze. While revenue grew to US$199.9m, driven by its ADHD portfolio, profitability was pressured by acquisition costs and authorized generics in pain treatments. The article discusses the bull case focused on ADHD growth and the bear case highlighting margin strain and declining pain brand revenues.
Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen
Wall Street Zen has downgraded Collegium Pharmaceutical (NASDAQ:COLL) from "Buy" to "Hold," leading to mixed analyst views but a consensus "Moderate Buy" rating with an average price target of $52.60. Despite exceeding Q2 earnings expectations with strong ADHD portfolio growth, the company lowered its full-year product revenue and adjusted EBITDA guidance due to weaker pricing and Nucynta performance, resulting in a GAAP net loss. Other analysts like Zacks, Needham, and Piper Sandler also adjusted their ratings or price targets, reflecting ongoing caution despite some positive growth areas.
Collegium Pharmaceutical (NASDAQ:COLL) Releases Earnings Results, Beats Estimates By $0.20 EPS
Collegium Pharmaceutical (NASDAQ:COLL) announced quarterly earnings that surpassed analyst estimates, reporting $1.92 EPS against a consensus of $1.72, and revenue of $199.88 million. The company experienced strong growth in its ADHD portfolio, particularly with JORNAY PM and the recent AZSTARYS acquisition, but faced declines in its pain portfolio products, leading to a reduction in full-year product-revenue and adjusted EBITDA guidance. Despite the mixed results and a GAAP net loss, the ADHD segment's performance and strategic acquisitions highlight the company's efforts to diversify its revenue streams.
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return
Collegium Pharmaceutical (COLL) stock has seen a 59.8% gain over five years, but a recent pullback and strong valuation checks suggest it may be undervalued. The company trades at a P/E of 12.6x, below the industry average, indicating a discount. Its future valuation depends on sustaining prescription demand and protecting margins to maintain earnings reliability.
Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside
Collegium Pharmaceutical, Inc. (COLL) has seen its average 12-month price target reduced from $53.6 to $51.2 by 5 analysts, with individual forecasts ranging from $43 to $60. Despite this cut, the updated target still implies a significant 43% potential upside from its August 5 closing price. The consensus rating for COLL remains a "Buy," with 4 analysts recommending Buy and 1 recommending Hold.
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return
Collegium Pharmaceutical (COLL) stock has seen a nearly 60% return over the past five years but may still be trading at a discount. Despite recent weakness, the company screens as undervalued in most measures, with its current P/E ratio of 12.6x being below the industry average. The market's lower valuation may reflect concerns about risks or business mix, and the stock's future performance hinges on its ability to sustain prescription demand and protect margins.
Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-08-07
Collegium Pharmaceutical, Inc. (COLL) released its Q2 2026 earnings call presentation. The company reported an EPS of $1.92, beating estimates by $0.16, and revenue of $199.88M, which missed estimates by $1.07M but represented a 6.32% year-over-year increase. This presentation provides details on their financial performance for the quarter.
Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Collegium Pharmaceutical Inc (COLL), detailing its current price momentum score, support and resistance levels, and indicator readings. It also covers moving average data and offers a technical summary, suggesting the stock is currently suitable for range-bound swing trading with a neutral signal based on technical indicators.
Collegium Pharmaceutical Releases Q2 2026 Financial Results
Collegium Pharmaceutical Inc. reported mixed Q2 2026 financial results, with adjusted earnings of $1.92 per share exceeding expectations, but revenue of $199.9M slightly missing estimates. The company's product, JORNAY PM, showed significant revenue growth of 41.0%, contributing to the positive outlook. Management issued full-year revenue guidance between $825.0M and $855.0M, and Wall Street maintains a positive sentiment with predominantly buy ratings.
Collegium Pharmaceutical falls 13% on weak revenue guidance By Investing.com
Collegium Pharmaceutical Inc. (NASDAQ:COLL) saw its shares tumble 13.5% after reporting second-quarter results that missed revenue expectations and issuing weaker-than-expected full-year guidance. While adjusted earnings per share beat estimates, revenue of $199.9 million fell short of analyst forecasts. The company updated its full-year 2026 revenue guidance to $825 million-$855 million, significantly below the previous outlook and analyst consensus, primarily due to lower-than-expected revenue from authorized generic versions of Nucynta.
Collegium Pharmaceutical falls 13% on weak revenue guidance
Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares dropped 13.5% after reporting Q2 results that missed revenue expectations and issuing weaker-than-expected full-year guidance. Although adjusted EPS beat estimates, revenue fell short, and the company lowered its 2026 revenue and adjusted EBITDA forecasts. The decline was primarily attributed to lower-than-expected revenue from generic versions of Nucynta.
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. reported strong Q2 2026 financial results, with net revenues up 6% year-over-year to $199.9 million, driven by a 41% increase in JORNAY PM revenue and the successful acquisition and initial sales of AZSTARYS. The company updated its full-year 2026 financial guidance, adjusting product revenues and Adjusted EBITDA due to lower-than-expected Nucynta AG revenue, while reaffirming and raising guidance for its ADHD portfolio. Collegium also highlighted strategic priorities including growth in its ADHD business, maximizing its pain portfolio, and capital deployment to enhance shareholder value.
Collegium Pharmaceutical (COLL): Principal Global Investors discloses 5% equity stake
Principal Global Investors has filed a Schedule 13G, reporting a passive 5% equity stake in Collegium Pharmaceutical, Inc. The firm beneficially owns 1,632,360 shares of common stock with shared voting and dispositive power. Both companies' principal offices are noted, with Collegium Pharmaceutical in Stoughton, Massachusetts, and Principal Global Investors in Des Moines, Iowa.
Collegium Pharmaceutical earnings ahead after ADHD acquisition
Collegium Pharmaceutical is set to report second-quarter earnings, with analysts anticipating increased revenue and earnings per share following the acquisition of ADHD medication AZSTARYS. Investors will closely watch the performance of AZSTARYS and the company's legacy pain medication portfolio, as well as updates on cost synergies from the acquisition. The company's stock is trading below its 52-week high, and the upcoming earnings report will be crucial in demonstrating the success of its diversification strategy.
Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.
Collegium Pharmaceutical is transitioning into a central nervous system (CNS) platform company by acquiring the ADHD drug franchise AZSTARYS for $650 million. This strategic move is expected to generate $60–70 million in revenue by 2026 from AZSTARYS and create over $50 million in annual synergies. The company projects total 2026 revenue between $865 million and $895 million, despite the market currently undervaluing its growth potential.
Vanguard Capital Management (COLL) discloses 5.01% passive stake in Collegium
Vanguard Capital Management LLC has disclosed a passive stake of 5.01% in Collegium Pharmaceutical Inc. common stock, totaling 1,625,821 shares, through a Schedule 13G filing. Vanguard holds sole voting power over 244,560 shares and sole dispositive power over all 1,625,821 shares. This filing aggregates holdings from Vanguard funds and managed accounts, with no other single person holding more than 5% interest in these reported securities.
Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Collegium Pharmaceutical Inc (COLL), noting its current valuation score of 8.50, which ranks 55 out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 15.00, comparing it to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
How Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investors
Collegium Pharmaceutical (COLL) reported better-than-expected quarterly revenue and earnings per share, but its full-year guidance was softer than analyst forecasts. This discrepancy has led investors to reconsider the company's medium-term growth prospects, particularly concerning its dependence on a focused pain and ADHD portfolio and upcoming patent expirations. Despite a projected fair value of $54.33, indicating a 51% upside, analysts are closely watching how the company navigates competitive and regulatory pressures.
Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Collegium Pharmaceutical Inc (COLL), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 7.30, ranking 37 out of 155 in the Pharmaceuticals industry, with a beta of 0.75 indicating underperformance in rising markets but smaller declines in falling markets. The report covers various metrics including VaR, maximum drawdown, volatility, and Sharpe ratio across different timeframes.
How Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investors
Collegium Pharmaceutical reported strong quarterly revenue and earnings that exceeded analyst estimates, but its full-year guidance was softer than expected. This divergence highlights investor focus on how the company's management views its medium-term growth and product momentum, especially given its concentrated portfolio in pain and ADHD, significant debt, and looming patent expirations. While the strong quarter supports current execution, the cautious outlook and existing risks like generic competition will influence the investment narrative and future stock performance.
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC reduced its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 9.1% in the first quarter, selling 147,900 shares but still owning 1.47 million shares valued at $48.6 million. Despite this sale, other institutional investors increased their holdings, and the company reported strong Q1 results, exceeding analyst expectations with $1.76 EPS and $193.5 million in revenue. Analysts maintain a "Buy" rating with an average price target of $57.50 for Collegium Pharmaceutical.
Collegium Pharmaceutical Inc (COLL) Financial Health: Profitability & Balance Sheet Analysis
Collegium Pharmaceutical Inc (COLL) currently has a financial score of 8.88, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $193.52 million, an 8.87% increase year-over-year, alongside a significant 499.75% year-over-year increase in net profit. While these positive financial indicators are highlighted, specific detailed data for categories like cash and cash equivalents, total assets, and free cash flow are noted as not yet disclosed by the company.
Collegium Pharmaceutical Inc. (COLL) Q4 2022 Earnings Report - Results, Call & Slides
This report details Collegium Pharmaceutical's (COLL) Q4 2022 earnings. The company reported actual EPS of $1.09, missing the consensus by less than $0.01, and actual revenue of $129.62 million, beating expectations by $4.40 million. The report includes details on the earnings announcement, an audio recording of the Q4 2022 earnings call, and Collegium Pharmaceutical's earnings history.
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
This article analyzes the Q1 performance of branded pharmaceutical stocks, highlighting Collegium Pharmaceutical as a key example. It discusses industry tailwinds like precision medicine and AI adoption, alongside headwinds such as regulatory scrutiny and patent cliffs. While Collegium Pharmaceutical's revenue beat expectations, its full-year guidance disappointed, leading to a stock dip, whereas Eli Lilly showed strong growth and Zoetis underperformed.
Collegium Pharmaceutical Inc
This article provides a detailed revenue breakdown for Collegium Pharmaceutical Inc. (COLL) by business segment and geographical region. It highlights major product contributions like Nucynta IR, Belbuca, and Xtampza ER, and notes that all revenue is generated within the United States. Key financial metrics such as market cap and P/E TTM are also included.
Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Collegium Pharmaceutical Inc (COLL) focusing on its dividends and stock splits. It highlights that the company has not distributed any dividends over the past five years and contains current stock price information. The page aims to present historical payout details and an event timeline, though no specific data is listed.
Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and shareholder types. Key data includes top shareholders like BlackRock Institutional Trust Company and Eventide Asset Management, as well as a breakdown of institutional shareholding trends over several quarters. The company's inclusion in various ETFs is also listed.
Collegium Pharmaceutical, Inc. Revenue Breakdown – FWB:354
The article details Collegium Pharmaceutical, Inc.'s revenue breakdown for the last year. The company generated 664.59 million EUR, with the Pharmaceutical segment being the top performer and the United States contributing the entirety of this revenue. This marks an increase from the previous year's 609.97 million EUR.
Collegium Pharmaceutical, Inc. Revenue Breakdown – BOATS:COLL
This article provides a revenue breakdown for Collegium Pharmaceutical, Inc. (COLL), highlighting its top-performing Pharmaceutical segment. In the last year, the company generated $780.57 million USD, with all of this revenue coming from the United States. This represents an increase from $631.45 million USD in the previous year.
Collegium Pharmaceutical Inc (COLL) Institutional Confidence
Collegium Pharmaceutical Inc (COLL) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 119.28%, a decrease of 6.89% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 4.53% of shares outstanding.
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its second quarter 2026 financial results before market open on Thursday, August 6, 2026. This will be followed by a live conference call and webcast at 8:00 a.m. ET to discuss the results. The company specializes in biopharmaceutical products for central nervous system and pain conditions, including ADHD medications JORNAY PM® and AZSTARYS®.
Collegium's Aug. 6 results will be followed by an 8 a.m. webcast
Collegium Pharmaceutical (NASDAQ: COLL) announced it will report its second-quarter 2026 financial results before the U.S. market opens on Thursday, August 6, 2026. The company will also host a live conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the call and webcast details through the company's investor relations section.
